Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Immunology

Background:

• RAS genes are frequently mutated oncogenes in various cancers, including colorectal cancer (CRC).
• RAS mutations confer resistance to anti-EGFR monoclonal antibody therapies in CRC patients.
• RAS mutations activate downstream signaling pathways, influencing the tumor microenvironment (TME).

Purpose of the Study:

• To review the literature on the effects of RAS mutations on the CRC tumor microenvironment.
• To explore how RAS mutations contribute to immune evasion and disease progression in CRC.
• To discuss strategies targeting mutant RAS and the TME for improved immunotherapy responses.

Main Methods:

• Literature review of existing studies on RAS mutations, CRC, tumor microenvironment, and immunotherapy.
• Analysis of molecular mechanisms linking RAS signaling to TME modulation.
• Synthesis of evidence on therapeutic approaches targeting mutant RAS and the TME.

Main Results:

• RAS mutations are associated with a TME that promotes immune evasion and disease progression.
• Specific mechanisms by which RAS mutations alter the TME are being elucidated.
• Targeting mutant RAS may sensitize CRC tumors to immunotherapy.

Conclusions:

• RAS mutations significantly influence the CRC tumor microenvironment, contributing to therapeutic resistance and immune evasion.
• Further research into RAS-TME interactions is crucial for developing effective CRC treatments.
• Targeting mutant RAS offers a promising avenue for enhancing immunotherapy efficacy in colorectal cancer.